VYNE Therapeutics Competitors

Pliant Therapeutics (NASDAQ:PLRX) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Insider & Institutional Ownership

79.5% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 50.1% of VYNE Therapeutics shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Pliant Therapeutics and VYNE Therapeutics, as reported by MarketBeat.com.

Pliant Therapeutics presently has a consensus price target of $45.50, suggesting a potential upside of 52.02%. VYNE Therapeutics has a consensus price target of $19.50, suggesting a potential upside of 264.83%. Given VYNE Therapeutics' higher probable upside, analysts clearly believe VYNE Therapeutics is more favorable than Pliant Therapeutics.

Valuation and Earnings

This table compares Pliant Therapeutics and VYNE Therapeutics' revenue, earnings per share and valuation.

Pliant Therapeutics has higher revenue and earnings than VYNE Therapeutics.

Profitability

This table compares Pliant Therapeutics and VYNE Therapeutics' net margins, return on equity and return on assets.

Summary

Pliant Therapeutics beats VYNE Therapeutics on 6 of the 10 factors compared between the two stocks.

VYNE Therapeutics (NASDAQ:VYNE) and Constellation Pharmaceuticals (NASDAQ:CNST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

50.1% of VYNE Therapeutics shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VYNE Therapeutics and Constellation Pharmaceuticals, as provided by MarketBeat.

VYNE Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 264.83%. Constellation Pharmaceuticals has a consensus target price of $45.2857, suggesting a potential upside of 103.17%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Constellation Pharmaceuticals.

Earnings and Valuation

This table compares VYNE Therapeutics and Constellation Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

VYNE Therapeutics has higher revenue and earnings than Constellation Pharmaceuticals. Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

VYNE Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, suggesting that its share price is 180% more volatile than the S&P 500.

Profitability

This table compares VYNE Therapeutics and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Summary

VYNE Therapeutics beats Constellation Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

VYNE Therapeutics (NASDAQ:VYNE) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

50.1% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 42.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by insiders. Comparatively, 70.6% of Kiniksa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VYNE Therapeutics and Kiniksa Pharmaceuticals, as provided by MarketBeat.

VYNE Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 264.83%. Kiniksa Pharmaceuticals has a consensus target price of $37.00, suggesting a potential upside of 136.72%. Given VYNE Therapeutics' higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Kiniksa Pharmaceuticals.

Earnings and Valuation

This table compares VYNE Therapeutics and Kiniksa Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

VYNE Therapeutics has higher revenue and earnings than Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

VYNE Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500.

Profitability

This table compares VYNE Therapeutics and Kiniksa Pharmaceuticals' net margins, return on equity and return on assets.

Summary

VYNE Therapeutics beats Kiniksa Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

VYNE Therapeutics (NASDAQ:VYNE) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

50.1% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 74.3% of Arcturus Therapeutics shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by insiders. Comparatively, 12.6% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VYNE Therapeutics and Arcturus Therapeutics, as provided by MarketBeat.

VYNE Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 264.83%. Arcturus Therapeutics has a consensus target price of $70.6667, suggesting a potential upside of 75.22%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Arcturus Therapeutics.

Earnings and Valuation

This table compares VYNE Therapeutics and Arcturus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Arcturus Therapeutics has higher revenue and earnings than VYNE Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

VYNE Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500.

Profitability

This table compares VYNE Therapeutics and Arcturus Therapeutics' net margins, return on equity and return on assets.

Summary

Arcturus Therapeutics beats VYNE Therapeutics on 9 of the 14 factors compared between the two stocks.

VYNE Therapeutics (NASDAQ:VYNE) and Zogenix (NASDAQ:ZGNX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

50.1% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 96.6% of Zogenix shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by insiders. Comparatively, 3.5% of Zogenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VYNE Therapeutics and Zogenix, as provided by MarketBeat.

VYNE Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 264.83%. Zogenix has a consensus target price of $58.25, suggesting a potential upside of 206.58%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Zogenix.

Earnings and Valuation

This table compares VYNE Therapeutics and Zogenix's top-line revenue, earnings per share (EPS) and valuation.

VYNE Therapeutics has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

VYNE Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Profitability

This table compares VYNE Therapeutics and Zogenix's net margins, return on equity and return on assets.

Summary

VYNE Therapeutics beats Zogenix on 8 of the 14 factors compared between the two stocks.

VYNE Therapeutics (NASDAQ:VYNE) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

50.1% of VYNE Therapeutics shares are held by institutional investors. 2.2% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VYNE Therapeutics and Praxis Precision Medicines, as provided by MarketBeat.

VYNE Therapeutics currently has a consensus target price of $19.50, suggesting a potential upside of 264.83%. Praxis Precision Medicines has a consensus target price of $60.3333, suggesting a potential upside of 120.44%. Given VYNE Therapeutics' higher possible upside, equities analysts plainly believe VYNE Therapeutics is more favorable than Praxis Precision Medicines.

Earnings and Valuation

This table compares VYNE Therapeutics and Praxis Precision Medicines' top-line revenue, earnings per share (EPS) and valuation.

Praxis Precision Medicines has lower revenue, but higher earnings than VYNE Therapeutics.

Profitability

This table compares VYNE Therapeutics and Praxis Precision Medicines' net margins, return on equity and return on assets.

Summary

VYNE Therapeutics beats Praxis Precision Medicines on 5 of the 7 factors compared between the two stocks.